Active substance: Hydroxyzine
Non-steroidal parent immune-dependent immunosuppressant NsIDI e. Thus, the combination of the NsIDI and the NsIDIE can be used as an anti-inflammatory immune composition of the invention as in the structural or functional analog thereof.
That the compounds useful in the present invention include readily applicable to all pharmaceutically described in the specification, the described just like those of the enantiomers diastereomers and enantiomers, salts, esters, solvates, and the transfected body polymorphs compound It includes racemic mixtures and pure isomers.
In one aspect, turning groups present invention is a non-steroidal parent immune-dependent immunosuppressant NsIDI and NsIDIE improver reduces the pro-inflammatory cytokine secretion in the bar, which living body, characterized in a composition containing a treating immunoinflammatory diseases It has a sufficient amount.
Alternatively, the compositions of the present invention are non-steroidal anti-inflammatory drug NSAID, COX-2 inhibitors, physiological disease modified anti rheumatic drug DMARD, xanthine, anticholinergic compound, beta receptor, bronchodilator, non-steroidal knife cine We calcineurin inhibitor, contains a vitamin D analog, bovine ralnen psoralen, retinoid, or 5-amino raises keulsan.
The present invention also provides a method of reducing the pro-inflammatory cytokine secretion, or the product of the patient.
The invention also features a method of reducing the pro-inflammatory cytokine secretion, or the product of the patient. In addition, the invention features a method of treating a patient which is a risk to have or has an immune-inflammatory disease.
The present invention also provides cells e.
The invention also features a composition method of inhibiting the secretion of pro-inflammatory cytokines that have to receive the therapeutic compounds useful in the patient.
The method comprises the steps of contacting the cells in vivo and NsIDI and the candidate compound, and NsIDI and the candidate is the composition of the compound in contact with the NsIDI but the candidate compound has a with respect to non-contacted cells stimulated to secrete the cytokine blood cells, or the candidate compounds include contact but NsIDI, the amount of reduction of the bar, cytokine comprising a step of determining whether to reduce the amount of cytokine in blood cells stimulated to secrete the cytokines for the non-contact cells are required for such a therapeutic composition indicate that useful for patients with.
NsIDI is cyclosporine cyclosporine, other Crawley commerce tacrolimus, ascomycin ascomycin, blood Mech Raleigh commerce pimecrolimus and a knife cine we other components like the inhibitors inhibit the knife cine we phosphatase activity of It comprises a peptide, or peptide analogues, transformed into peptides, peptide fragments, chemically.
NsIDI also includes rapamycin and Plymouth Avenue Raleigh everolimus in combination with the FK 506- binding protein to prevent the antibody-induced proliferation of white blood cells and cytokine secretion.
This selective serotonin uptake inhibitors, tricyclic hyperactivity tablets, phenoxy phenols e. Types of antihistamines include, but are not limited, divided into ethanolamine, ethylenediamine, phenothiazine, alkylamines, piperazine and piperidine.
It illustrates an example of SSRI used in the present invention. Exemplary tricyclic hyperactivity tablets motilin maprotiline, amorphous Safin amoxapine, 8- hydroxy amorphous Safin, 7-hydroxy amorphous Safin, green Safin loxapine, green Safin succinate as Marv, green Safin hydrochloride, 8-hydroxy-lock Safin, amido trip motilin amitriptyline, claw US plastic Min clomipramine, poison sepin doxepine, imipramine impramine, tree US plastic Min trimipramine, desipramine desipramine, Note the lip motilin nortriptyline, and professional trips motilin protriptyline.
Natural corticosteroids are generally produced by the adrenal cor-Tex adrenal cortex. If it is not, thereby changing the immune system in the immune pro-dependent manner.
The "patient" includes any animal human body as an example. In other animals treated using the methods of the present invention, compositions, and kits horses, dogs, cats, pigs, goats, rabbits, hamsters, monkeys, guinea pigs, mice, rats, lizards, snakes, sheep, cattle, fish, and a new one.
In one embodiment of the present invention, a patient of applying the technology SSRI or TCA treatment target is clinically stable, depression, anxiety, obsessive, alcoholism, anorexia, concentration deficiencies, the boundary adult prices disorder, insomnia, headaches, premenstrual syndrome, irregular heart does not have a heartbeat, schizophrenia, Tourette's syndrome, or phobias.
Ultimately, it is prepared to determine the appropriate amount taking prescribed. Efficacy is preferably measured by one skilled in using a standard method that meets a predetermined instruction.